IIAR Journals’ Post

Relapse Multiple Myeloma (MM) patients urgently need more effective therapies. Vrije Universiteit Amsterdam (VU Amsterdam) Takeda Molecular Templates publish a nice study on the development of a toxin body (CD38 scFv linked to Shiga-like toxin A) synthesized by ATUM. The toxin body its internalized and the Shiga-like toxin cause cell death to MM cells with minimal toxicity to non-MM cells. Toxin body also show efficient in-vivo activity in mouse xenograft models. https://lnkd.in/gvRw8Kab

#Review NIR-II Aggregation-Induced Emission Luminogens for Tumor Phototheranostics by Yonghong Tan, Peiying Liu, Danxia Li, Dong Wang and Ben Zhong Tang https://lnkd.in/d-HWYByq MDPI Shenzhen University The University of Hong Kong #NIRIIemission #phototheranostics #cancertreatment #openaccess #Abstract As an emerging and powerful material, aggregation-induced emission luminogens (AIEgens), which could simultaneously provide a precise diagnosis and efficient therapeutics, have exhibited significant superiorities in the field of phototheranostics. Of particular interest is phototheranostics based on AIEgens with the emission in the range of second near-infrared (NIR-II) range (1000–1700 nm), which has promoted the feasibility of their clinical applications by virtue of numerous preponderances benefiting from the extremely long wavelength. In this minireview, we summarize the latest advances in the field of phototheranostics based on NIR-II AIEgens during the past 3 years, including the strategies of constructing NIR-II AIEgens and their applications in different theranostic modalities (FLI-guided PTT, PAI-guided PTT, and multimodal imaging-guided PDT–PTT synergistic therapy); in addition, a brief conclusion of perspectives and challenges in the field of phototheranostics is given at the end.

Have your ever heard of immunogenic cell death (ICD)? Our PhD student Egor Matnurov will explain it to you in his video. ✍ ICD-inducing agents can trigger localized cell death and induce an immune response to potentially overcome metastatic and relapsing tumors. ✍Do metal complexes, based on platinum, ruthenium, irhidium, have clinical potential as ICD-inducing therapeutic agents? If you want to know more about it, watch our video and read this review: L. Zhang, N. Montesdeoca, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2023, 62, e202300662 #ICD #immunogeniccelldeath #immunotherapy #immunesystem #anticancerdrugs #research

Our experience of clinical iPSC lines showing differntiation into NK cells. More information including live imaging of human iNK cells engulfing K562 cells, availabe through below link!

🚨 Exciting Webinar Alert! 🚨 Join us on November 27th, 2024 for a deep dive into the cutting-edge world of Peptide-Drug Conjugates (PDCs) for the precise treatment of Pulmonary Fibrosis! 🎤 Presented by Dr. Kelly Bugatti from the University of Parma, Italy, this session will explore the latest advancements in targeted therapy using PDCs, designed to selectively deliver nintedanib (a potent kinase inhibitor) for the treatment of pulmonary fibrosis. 🧬 Key Topics: · Understanding the mechanism of PDCs · How PDCs can revolutionize drug delivery for pulmonary fibrosis · In vitro and in vivo evaluations of promising PDC candidates 🔬 Don’t miss this unique opportunity to stay ahead of the curve in biomedical research! 👉 REGISTER NOW: https://lnkd.in/gtrcVJXy 🗓️ November 27, 2024 🕙 10:00 EST | 16:00 CET 🔗 https://lnkd.in/gcKvT_PX #BOCSciences #Webinar #PeptideDrugConjugates #PulmonaryFibrosis #TargetedTherapy #BiomedicalResearch #ScienceWebinar

Enhancing Quality Control in Cell Therapies Cell therapies have revolutionized the field of regenerative medicine, offering promising treatments for a variety of medical conditions. Maintaining the safety, efficacy, and consistency of cell-based therapies is paramount for their successful application in clinical settings. Quality control measures play a vital role in evaluating the quality of these therapies, from development to administration. This article explores the current approaches to quality control in cell therapies, including the utilization of functional measurement techniques such as transepithelial electrical resistance (TEER), to ensure the quality and safety of these promising treatments. https://lnkd.in/gN5PHh8B Stop by booth 1930 to see our novel microinjector for RPE and IO injections and our automated TEER system for high throughput screening of barrier integrity and RPE layer functionality!, ARVO in Seattle, May 5-9. #worldprecision

One of the research directions of our group is the development of novel #therapeutic agents capable of activating #immune system in #cancer #patients. These agents are called ICD inducers. We will dedicate this week to the overview of the recent findings in the field of metal-based ICD inducers. Stay tuned for our monthly newsletter to know more about our own ICD-inducing drug candidates. #ICD #immunogeniccelldeath #immunotherapy #immunesystem #anticancerdrugs #research

Particle Therapy Market worth $ 1.1 billion by 2028 Download Free Sample Report : https://lnkd.in/dNATeDku The global particle therapy market in terms of revenue was estimated to be worth $0.7 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 8.2% from 2023 to 2028. Particle therapy market: Market Dynamics ✅ Driver: Growing global prevalence of cancer ✅Increasing number of particle therapy centers worldwide ✅Restraint: Affordability and accessibility of treatments ✅Opportunity: Rising healthcare expenditure across developing countries As of 2022, prominent players in the market are IBA (EU), Varian Medical Systems Pacific Inc (US), and Hitachi – Global Research (Japan), among others. #ParticleTherapy #CancerTreatment #RadiationTherapy #ProtonTherapy #OncologyInnovation

I think of radiopharmaceuticals as close cousins of cell therapy in the delivery complexity but there is so much more nuance there. They also appeal to the “precision is better” part of my brain. Hence super excited to learn a lot more from Matthew Furlow, Ph.D. , Jedediah Seltzer, Ph.D. Sankalp Sethi and Josh Hattem. We were witnessing the many ways of delivering precision care come together all at once! #radiopharma #precisionmedicine https://lnkd.in/esYKtk7Y

Our "Scar-in-a-jar" #assay has proved very popular recently. "Scar-in-a-jar" is an in vitro assay for the quantification of key markers of fibrosis. The assay provides a robust disease relevant readout to measure extracellular matrix deposition. The assay can used for medium throughput compound profiling and can be adapted to model #fibrosis in different tissues by altering the source of the cells used. Find out more in our white paper: https://lnkd.in/eyg3Yn-E #Domainex #DrugDiscovery